Immunome Inc. (IMNM) insider buying and selling

NASDAQ: IMNM · Source: SEC Form 4 filings · Latest trade reported

In the last 90 days at Immunome Inc. (IMNM), no insider made an open-market purchase and 1 insider made 3 open-market sales worth $2.2M, as reported on SEC Form 4. All 3 sales were scheduled in advance or made to cover tax on vesting shares, so they say less about the insider's view of the stock. Over the last 12 months, 2 insiders bought $808K of the stock, led by CLAY B SIEGALL (CEO), who bought $501K on Mar 27, 2026; 5 insiders sold $4.6M, of which $4.4M was scheduled or tax-related.

Insider buys, 90 days
0
$0 · 0 insiders
Insider sales, 90 days
3
$2.2M · 1 insider
Insider buys, 12 months
5
$808K · 2 insiders
Insider sales, 12 months
9
$4.6M · 5 insiders

This is the public summary. Create a free account to see IMNM’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock IMNM

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

Open-market insider trades at Immunome Inc.
DateInsiderTypeSharesPriceValue
JEAN JACQUES BIENAIME
Director
Open market purchase
3 trades
10,500avg. $19.45$204K
JEAN JACQUES BIENAIME
Director
Open market sale
2 trades
10,500avg. $19.41$204K
JEAN JACQUES BIENAIME
Director
Open market purchase5,000$20.70$104K
CLAY B SIEGALL
CEO
Open market purchase25,450$19.67$501K

Scheduled and tax-related sales

Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.

Scheduled and tax-related insider sales at Immunome Inc.
DateInsiderTypeSharesPriceValue
Isaac Barchas
Director
10b5-1 sale
3 trades
83,464avg. $26.35$2.2M
Kinney Horn
CHIEF BUSINESS OFFICER
10b5-1 sale1,092$25.00$27K
Robert Lechleider
Chief Medical Officer
10b5-1 sale
2 trades
55,000avg. $19.85$1.1M
Max Rosett
CFO
10b5-1 sale60,000$18.23$1.1M

What the IMNM insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Immunome Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with IMNM Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about IMNM insider trading

Who bought Immunome Inc. (IMNM) stock recently?

Insiders who bought Immunome Inc. stock on the open market in the last 12 months: CLAY B SIEGALL ($501K), JEAN JACQUES BIENAIME ($308K). The most recent purchase was reported on Jun 5, 2026.

Are insiders buying or selling IMNM?

Over the last 12 months insiders were net buyers of IMNM on discretionary trades: $808K bought against $204K sold (scheduled and tax-related sales excluded).

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see IMNM in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.